Boehringer Ingelheim And 3T Biosciences Enter Into A Second Partnership To Develop Next-Generation Cancer Immunotherapies January 10, 2024
Orion and MSD Announce Initiation of Two Ph 3 Trials of ODM-208/MK5684 in Certain Patients with Metastatic CRPC January 10, 2024
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma January 10, 2024
Innate Pharma Announces Licensing Of A Fourth Natural Killer Cell Engager In Oncology To Sanofi January 10, 2024
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics January 10, 2024
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio January 10, 2024
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases January 10, 2024
Merck to Acquire Harpoon Therapeutics, including HPN328 in certain patients with small cell lung cancer and neuroendocrine tumors January 10, 2024
Avenzo Therapeutics Announces Global License Of AVZO-021 (ARTS-021), A Clinical Stage CDK2 Inhibitor From Allorion Therapeutics January 10, 2024
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million January 10, 2024
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted ADC January 10, 2024
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs January 10, 2024
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications January 10, 2024
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications January 6, 2024
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program December 19, 2023
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1 December 19, 2023
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform December 19, 2023
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) December 19, 2023
Sarclisa Ph 3 trial met primary endpoint of PFS in patients with newly diagnosed multiple myeloma not eligible for transplant December 11, 2023
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer December 11, 2023
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced RCC December 11, 2023
HiberCell and Merck to Evaluate HC-7366 + WELIREG (belzutifan) in Ph 1b Study of ccRCC Patients December 11, 2023
ONK Therapeutics and NAYA Biosciences Announce Research Partnership to Advance Combination Therapy of Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies and FLEX-NK Bispecific Antibodies December 11, 2023
